A quinone derivative is represented by general formula (1). In general formula (1), at least one of R.sup.1-R.sup.3 and at least one of R.sup.4-R.sup.6 each represent, independently of one another, an alkyl group having 4 to 10 carbon atoms or an alkyl group having 2 to 5 carbon atoms that has an aryl group having 6 to 14 carbon atoms. All other of R.sup.1-R.sup.3 and all other of R.sup.4-R.sup.6 each represent, independently of one another, an alkyl group having 1 to 6 carbon atoms, an aryl group having 6 to 14 carbon atoms, or a cycloalkyl group having 3 to 10 carbon atoms.

##STR00001##

Process for preparation of MK-7 type of vitamin K2 is characterized by attaching hexaprenyl chain of “all-trans” configuration to monoprenyl derivative of menadiol following “1+6” synthetic strategy. According to the invention, a-sulfonyl carbanion generated in situ from the protected monoprenyl menadiol of the formula (II), wherein R.sub.1 represents C.sub.1-3-alkyl group, is reacted with hexaprenyl halide of the formula (VII), wherein X represents halogen atom, preferably bromine, both Z′ and Z′ represent H or one of Z′ and Z″ represents H and the other represents phenylsulfonyl group —SO.sub.2Ph in the alkylation reaction. The hexaprenyl halide of formula (VII) is obtained by coupling two triprenyl units in alkylation reaction, with or without separation of the intermediates. ##STR00001##

Process for preparation of MK-7 type of vitamin K2 is characterized by attaching hexaprenyl chain of “all-trans” configuration to monoprenyl derivative of menadiol following “1+6” synthetic strategy. According to the invention, a-sulfonyl carbanion generated in situ from the protected monoprenyl menadiol of the formula (II), wherein R.sub.1 represents C.sub.1-3-alkyl group, is reacted with hexaprenyl halide of the formula (VII), wherein X represents halogen atom, preferably bromine, both Z′ and Z′ represent H or one of Z′ and Z″ represents H and the other represents phenylsulfonyl group —SO.sub.2Ph in the alkylation reaction. The hexaprenyl halide of formula (VII) is obtained by coupling two triprenyl units in alkylation reaction, with or without separation of the intermediates. ##STR00001##

The present invention provides processes for the preparation of 3, 5-Dihydroxy-4-isopropyl-trans-stilbene or a salt or solvate thereof and novel intermediates used therein. In some embodiments the 3, 5-Dihydroxy-4-isopropyl-trans-stilbene is prepared from (E)-2-chloro-2-isopropyl-5-styrylcyclohexane-1,3-dione. Also disclosed are crystal forms of 3, 5-Dihydroxy-4-isopropyl-trans-stilbene or a salt or solvate thereof and pharmaceutical compositions comprising same.

The present invention provides processes for the preparation of 3, 5-Dihydroxy-4-isopropyl-trans-stilbene or a salt or solvate thereof and novel intermediates used therein. In some embodiments the 3, 5-Dihydroxy-4-isopropyl-trans-stilbene is prepared from (E)-2-chloro-2-isopropyl-5-styrylcyclohexane-1,3-dione. Also disclosed are crystal forms of 3, 5-Dihydroxy-4-isopropyl-trans-stilbene or a salt or solvate thereof and pharmaceutical compositions comprising same.

1,3-Dipole-functional compounds (e.g., azide functional compounds) can be reacted with certain alkynes in a cyclization reaction to form heterocyclic compounds. Useful alkynes (e.g., strained, cyclic alkynes) and methods of making such alkynes are also disclosed. The reaction of 1,3-dipole-functional compounds with alkynes can be used for a wide variety of applications including the immobilization of biomolecules on a substrate.

1,3-Dipole-functional compounds (e.g., azide functional compounds) can be reacted with certain alkynes in a cyclization reaction to form heterocyclic compounds. Useful alkynes (e.g., strained, cyclic alkynes) and methods of making such alkynes are also disclosed. The reaction of 1,3-dipole-functional compounds with alkynes can be used for a wide variety of applications including the immobilization of biomolecules on a substrate.

A compound has a structure represented by the following formula (C1): ##STR00001##
wherein R.sub.a1, R.sub.a2, R.sub.a3, R.sub.a41, R.sub.a42, R.sub.a43, R.sub.a44, R.sub.a45, R.sub.a5, R.sub.a6, R.sub.a7, R.sub.a8, R.sub.a9, R.sub.a10, and R.sub.a11 each independently represent a hydrogen atom, an alkyl group, an alkenyl group, an alkynyl group, an alkoxy group, an aralkyl group, an aryl group, a cyano group, a halogen atom, or a group obtained by combining two or more of the above groups, and a combination of R.sub.a1 and R.sub.a2, R.sub.a41 and R.sub.a42, R.sub.a42 and R.sub.a43, R.sub.a43 and R.sub.a44, R.sub.a44 and R.sub.a45, R.sub.a5 and R.sub.a6, R.sub.a8 and R.sub.a9, or R.sub.a10 and R.sub.a11 each independently may form a ring.

A compound has a structure represented by the following formula (C1): ##STR00001##
wherein R.sub.a1, R.sub.a2, R.sub.a3, R.sub.a41, R.sub.a42, R.sub.a43, R.sub.a44, R.sub.a45, R.sub.a5, R.sub.a6, R.sub.a7, R.sub.a8, R.sub.a9, R.sub.a10, and R.sub.a11 each independently represent a hydrogen atom, an alkyl group, an alkenyl group, an alkynyl group, an alkoxy group, an aralkyl group, an aryl group, a cyano group, a halogen atom, or a group obtained by combining two or more of the above groups, and a combination of R.sub.a1 and R.sub.a2, R.sub.a41 and R.sub.a42, R.sub.a42 and R.sub.a43, R.sub.a43 and R.sub.a44, R.sub.a44 and R.sub.a45, R.sub.a5 and R.sub.a6, R.sub.a8 and R.sub.a9, or R.sub.a10 and R.sub.a11 each independently may form a ring.

The present application relates to compounds and methods for reducing the severity of convulsant activity or epileptic seizures, or for the treatment of chronic or acute pain.